Tilray's Rescheduling Rally Keeps Fading -- Where Will the Stock Be if Washington Stalls Again?
Tilray Brands' stock has fallen from a 52-week high of $23.20 to around $5, despite a U.S. regulatory shift that reclassified marijuana products from Schedule I to Schedule III. The company's recent financial results showed a 25% revenue increase to $281.7 million, but this was largely due to a $53.7 million acquisition. Tilray's core beverage revenue declined 17% excluding the acquisition. The company's net loss per share improved to $0.43 from $13.01 year-over-year, but this was influenced by
How this was made
The 30-second read
Why it matters
The earnings release confirms modest growth and a narrowing loss, but organic revenue decline raises concerns about sustainable profitability.
Market read
Earnings data provides fresh insight into Tilray's financial health and the broader cannabis sector's reaction to regulatory changes.
What to watch
Potential upside from the BrewDog asset integration and future product diversification beyond beverage sales.
Background
Tilray's stock rallied after the U.S. federal rescheduling of medical marijuana to Schedule III, but has since fallen sharply amid weak earnings.
Ticker impact
Tilray reported Q4 FY2026 results with $281.7M revenue and a net loss of $0.43 per share, marking the first public disclosure of these numbers.
Potential further downside as the market digests weak top‑line growth and limited profit improvement.
Revenue growth was driven largely by a recent acquisition; organic beverage revenue fell 17% and guidance remains unclear, suggesting limited upside.
Market effects
Highlights ongoing challenges for U.S. cannabis firms despite federal rescheduling, possibly dampening sector sentiment.
U.S. cannabis market faces regulatory uncertainty; Canadian peers may see similar pressure.
Limited, confined to cannabis sector investors.
Counterpoint
If broader rescheduling occurs, Tilray could benefit from a first‑mover advantage in a nascent U.S. market.
Key entities
- CompanyTilray Brands
U.S.-listed cannabis producer (NASDAQ: TLRY).
- CompanyBrewDog
U.K. craft brewer whose assets were acquired by Tilray.
